A recombinant ADAMTS-13 is showing promise for the treatment of patients with congenital thrombotic thrombocytopenic purpura (cTTP). A phase 1 multi-centre study of the new therapy in patients with severe congenital ADAMTS-13 deficiency found it behaved similarly to the endogenous enzyme and restored ADAMTS-13 activity. The researchers observed normalisation of the structure of von Willebrand ...
New treatment in the pipeline for rare clotting disorder
By Mardi Chapman
21 Sep 2017